Protara Therapeutics Inc (TARA)
3.74
+0.03
(+0.81%)
USD |
NASDAQ |
May 16, 16:00
3.83
+0.09
(+2.41%)
After-Hours: 07:22
Protara Therapeutics Research and Development Expense (Quarterly): 7.748M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.748M |
| December 31, 2023 | 6.381M |
| September 30, 2023 | 6.218M |
| June 30, 2023 | 7.247M |
| March 31, 2023 | 5.143M |
| December 31, 2022 | 4.989M |
| September 30, 2022 | 3.466M |
| June 30, 2022 | 3.084M |
| March 31, 2022 | 5.269M |
| December 31, 2021 | 4.068M |
| Date | Value |
|---|---|
| September 30, 2021 | 4.093M |
| June 30, 2021 | 5.887M |
| March 31, 2021 | 7.04M |
| December 31, 2020 | 3.652M |
| September 30, 2020 | 2.796M |
| June 30, 2020 | 2.47M |
| March 31, 2020 | 3.065M |
| December 31, 2019 | 0.7148M |
| September 30, 2019 | 1.099M |
| June 30, 2019 | 0.9867M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.7148M
Minimum
Dec 2019
7.748M
Maximum
Mar 2024
4.271M
Average
4.080M
Median
Research and Development Expense (Quarterly) Benchmarks
| AngioDynamics Inc | 8.189M |
| Regulus Therapeutics Inc | 6.04M |
| Bio-Path Holdings Inc | 2.276M |
| Outset Medical Inc | 12.64M |
| AN2 Therapeutics Inc | 14.66M |